sIPV batch 3 — Competitive Intelligence Brief

sIPV batch 3 (sIPV batch 3) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated viral vaccine Poliovirus types 1, 2, and 3 Immunology / Infectious Disease Biologic

Target snapshot

sIPV batch 3 (sIPV batch 3) — Institute of Medical Biology, Chinese Academy of Medical Sciences. sIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
sIPV batch 3 TARGET	sIPV batch 3	Institute of Medical Biology, Chinese Academy of Medical Sciences	marketed	Inactivated viral vaccine	Poliovirus types 1, 2, and 3
sIPV batch 1	sIPV batch 1	Institute of Medical Biology, Chinese Academy of Medical Sciences	marketed	Inactivated viral vaccine	Poliovirus types 1, 2, and 3
fIPV (0.1 mL) ID	fIPV (0.1 mL) ID	Centers for Disease Control and Prevention	marketed	vaccine	poliovirus types 1, 2, and 3 antigens
2wIPV+1sIPV	2wIPV+1sIPV	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine	Poliovirus types 1, 2, and 3 antigens
oral polio vaccine + information	oral polio vaccine + information	Bandim Health Project	marketed	Live attenuated vaccine	Poliovirus types 1, 2, and 3
IPV at 6 weeks of age	IPV at 6 weeks of age	Centers for Disease Control and Prevention	marketed	Inactivated viral vaccine	Poliovirus types 1, 2, and 3
DTacP-IPV combined vaccine (TETRAXIM™)	DTacP-IPV combined vaccine (TETRAXIM™)	Sanofi	marketed	Combination inactivated vaccine	Diphtheria toxin, tetanus toxin, Bordetella pertussis antigens (PT, FHA, PRN), poliovirus types 1, 2, and 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

1. Sinovac Biotech Co., Ltd · 9 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
3. GlaxoSmithKline · 5 drugs in this class
4. Valneva Austria GmbH · 4 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Centers for Disease Control and Prevention · 3 drugs in this class
7. China National Biotec Group Company Limited · 2 drugs in this class
8. Statens Serum Institut · 2 drugs in this class
9. Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
10. Crucell Holland BV · 2 drugs in this class